Physician profile
Tracy E Thompson
NPI 1811923873
$637.77
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $62.66 · 2021: $187.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $92.77 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $60.20 | 2019 | |
| Aytu Biopharma, INC. | $55.04 | 2019 | |
| Tris Pharma INC | $53.75 | 2020-2021 | |
| Sanofi Pasteur INC. | $51.95 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.37 | 2019-2021 | |
| Pfizer INC. | $43.23 | 2019 | |
| Adlon Therapeutics L.P. | $42.35 | 2019-2021 | |
| Genentech USA, INC. | $34.23 | 2020-2021 | |
| Shire North American Group INC | $32.10 | 2019 | |
| Neos Therapeutics, LP | $30.60 | 2019 | |
| Glaxosmithkline, LLC. | $23.73 | 2019 | |
| Kaleo, INC. | $18.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.73 | 2021 | |
| Cranial Technologies, INC | $14.64 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $12.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.